Pharmacogenomic Testing to Guide Personalized Cancer Medicine Decisions in Private Oncology Practice: A Case Study

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Molecular tumor profiling is crucial for personalized cancer therapy.
• Limited adoption of these advanced technologies in private oncology practices hinders progress.
• Translating complex molecular data into actionable clinical insights remains a challenge.

Purpose of the Study:

• To evaluate the impact of molecularly guided interventions on cancer patient outcomes in a private oncology center.
• To assess the efficacy of precision medicine strategies based on pharmacogenomic profiling.
• To demonstrate the feasibility and benefits of integrating tumor profiling into routine clinical decision-making.

Main Methods:

• Analysis of molecular profiling data from 17 cancer patients undergoing targeted therapies.
• Utilized OncoDEEP™ profiling solutions to identify actionable tumor biomarker-drug response relationships.
• Retrospective review of clinical outcomes, including disease response rates and therapy progression.

Main Results:

• Molecularly guided interventions led to improved overall disease response rates.
• Earlier profiling and targeted therapy resulted in more durable and enhanced pharmacological responses.
• A case study showed a complete response in metastatic gastric adenocarcinoma with off-label therapy guided by profiling.

Conclusions:

• Pharmacogenomic-derived recommendations positively impacted cancer therapy progression.
• Early molecular tumor profiling enhances decision-making and improves outcomes in private oncology practice.
• Precision medicine strategies based on tumor profiling offer a viable paradigm for routine oncology care.